APOA5 and metabolic syndrome: In the future, the expression of mimics of such miRNAs or others would represent a novel approach to decrease the activity of PC7 and reduce the processing of its downstream substrates, e.g., TfR1, or partners, such as apoA-V and apoB, with pharmacological applications in the treatment of fatty liver disease and dyslipidemia.